News | October 18, 2023
Syngene Q2 FY23-24 revenue from operations up 18.5% to Rs 910 Cr
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
Lupin enters into BTA with Lupin Manufacturing Solutions
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Evonik China and Shandong Vland Biotech agreed to build a joint venture to expand their presence in gut health solutions products for farm animals globally
The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Increased capability to produce medicines for challenging diseases including cancer
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
